Baltimore, MD, May 7, 2015 – Harpoon Medical, a medical device company focused on minimally invasive mitral valve repair, announced today that it has enrolled the initial three patients in an Early Feasibility Study of its repair system for the minimally invasive, beating-heart treatment of MR….
Glasgow, United Kingdom, April 13th 2015 – Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the…
Apellis’ CEO, Cedric Francois, outlines the company thoughts regarding the emergence of immunotherapy as a therapeutic approach that focuses on correcting the underlying immune dysregulation rather than addressing the symptoms of a conditions. In particular, the article discusses how the complement system plays a key role…
Brighton, Sussex, February 11th 2015 – ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured £1.6m ($2.4m) in initial Series-A financing from Epidarex Capital. The proceeds will fund, in parallel, low molecular weight drug…
Crestwood, KY – February 10th 2015 – Apellis Pharmaceuticals, Inc. announced that it has begun the Phase I clinical trial of its drug compound APL-2 in patients suffering from age-related macular degeneration (AMD). The trial, labeled ASAP II, will focus on establishing safety of intravitreal…
By Scott Dance, The Baltimore Sun Within a year and a half of launching as a startup, Harpoon Medical’s heart surgery device could be used on humans for the first time in a matter of weeks. The Kent Island-based company expects doctors in Poland to…
Crestwood, KY – December 2nd 2014 – Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock. The financing was led by Morningside Ventures and AJU IB…
EDINBURGH, UK, December 2, 2014 – SIRAKOSS, an innovative medical device company based in Edinburgh and Aberdeen today announced it has secured $4.8m (£3.1m) in Series-A financing from a syndicate of investors led by Epidarex Capital. Synthetic bone grafts are used in trauma, spinal and…
CRESTWOOD, KY November 20, 2014 – Apellis Pharmaceuticals Inc. Complement inhibition is the only mechanism thus far to show reductions in the growth of dry AMD. Potentia was the first company to develop a complement inhibitor for the treatment of AMD. APL-2 has the same…
October, 2014 – Epidarex is a specialist life science venture capital group that recently raised a new fund of £47.5 million dedicated to UK start ups and university spin outs. Backers include US drug giant Eli Lilly, the Universities of Edinburgh, Glasgow and Aberdeen, King’s…